Medical School
UT Southwestern Medical School (1996)
UT Southwestern Medical Center (2000), Internal Medicine
University of California at San Diego School of Medicine (2005), Pulmonary Diseases & Critical Care Medicine

Research Interest

  • Pulmonary Hypertension


Featured Publications LegendFeatured Publications

Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.
Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, Langleben D, Lumens J, Naeije R Eur. Respir. J. 2019 Jan 53 1
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N Eur. J. Heart Fail. 2019 Jan
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V J. Heart Lung Transplant. 2019 Jan 38 1 43-50
Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension.
Darsaklis K, Dickson ME, Cornwell W, Ayers CR, Torres F, Chin KM, Matulevicius S Int J Cardiovasc Imaging 2016 Apr
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Hardin EA, Chin KM Drug Des Devel Ther 2016 10 3747-3754
Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center.
Chin KM, Ruggiero R, Bartolome S, Velez-Martinez M, Darsaklis K, Kingman M, Harden S, Torres F Pulm Circ 2015 Sep 5 3 513-20
Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: A Systematic Review and Meta-Analysis.
Pandey A, Garg S, Khunger M, Garg S, Kumbhani DJ, Chin KM, Berry JD Circ Heart Fail 2015 Jul
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.
Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V Am. Heart J. 2014 Feb 167 2 218-225.e1
Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.
Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM J. Am. Coll. Cardiol. 2013 Dec 62 25 Suppl D22-33
Association of Cardiac Troponin I With Disease Severity and Outcomes in Patients With Pulmonary Hypertension.
Vélez-Martínez M, Ayers C, Mishkin JD, Bartolome SB, García CK, Torres F, Drazner MH, de Lemos JA, Turer AT, Chin KM Am. J. Cardiol. 2013 Mar


Featured Books Legend Featured Books

Honors & Awards

  • Finalist, Alfred Soffer Research Award
    ACCP Original Research Award (2007)
  • College of Natural Sciences College Scholar Award
  • Southwestern Medical Foundation Medical School Scholarship 1992-1996
  • College of Natural Science Dean’s Honor List 1989-1992

Professional Associations/Affiliations

  • American College of Chest Physicians
  • American Medical Association
  • American Thoracic Society
  • Pulmonary Hypertension Association